UCB Group - Product Pipeline Review - Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “UCB Group - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “UCB Group - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- UCB Group - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of UCB Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of UCB Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the UCB Group’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate UCB Group’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of UCB Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the UCB Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with UCB Group.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of UCB Group and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
UCB Group Snapshot
UCB Group Overview
Key Information
Key Facts
UCB Group – Research and Development Overview
Key Therapeutic Areas
UCB Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
UCB Group – Pipeline Products Glance
UCB Group – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
UCB Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
UCB Group – Drug Profiles
Rotigotine
Product Description
Mechanism of Action
R&D Progress
Brivaracetam
Product Description
Mechanism of Action
R&D Progress
Cimzia
Product Description
Mechanism of Action
R&D Progress
Vimpat
Product Description
Mechanism of Action
R&D Progress
Brivaracetam
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
CDP6038
Product Description
Mechanism of Action
R&D Progress
CDP791
Product Description
Mechanism of Action
R&D Progress
Keppra
Product Description
Mechanism of Action
R&D Progress
Rotigotine
Product Description
Mechanism of Action
R&D Progress
Vimpat
Product Description
Mechanism of Action
R&D Progress
CDP7657
Product Description
Mechanism of Action
R&D Progress
UCB 2892
Product Description
Mechanism of Action
R&D Progress
UCB Group – Pipeline Analysis
UCB Group – Pipeline Products by Therapeutic Class
UCB Group - Pipeline Products By Target
UCB Group – Pipeline Products by Route of Administration
UCB Group – Pipeline Products by Molecule Type
UCB Group – Recent Pipeline Updates
UCB Group - Dormant Projects
UCB Group - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Alprostadil
CDP 484
CDP 571
CDP 860
CDP323
UCB4412
Vimpat
UCB Group – Company Statement
UCB Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 14, 2010: Immunomedics And UCB Initiate Phase III Program With Epratuzumab In Systemic Lupus Erythematosus
Dec 10, 2010: UCB Reports Study Results Of Neupro In Parkinson’s Disease
Dec 07, 2010: UCB Reports Long-term Use Of Vimpat C-V Effectively Reduces Partial-Onset Seizure Frequency
Dec 01, 2010: Synosia Announces Publication Of Data On SYN-115 In The Journal of Neuroscience
Nov 23, 2010: UCB Reports Neupro Improved Motor, Sleep And Non-Motor Symptoms Of Parkinson’s Disease In Large-scale Study
Nov 05, 2010: UCB To Present Data On Cimzia For Treatment Of Rheumatoid Arthritis At ACR Meeting
Nov 05, 2010: UCB To Present Data On Cimzia For Treatment Of Rheumatoid Arthritis At ACR Meeting
Oct 18, 2010: UCB Presents Growing Body Of Long-term Efficacy Data At ACG 2010 Meeting To Further Support Treatment With Cimzia In Crohn's Disease
Oct 15, 2010: UCB To Present Long-Term Data On Cimzia For Moderate To Severe Crohn's Disease At ACG Annual Meeting
Sep 30, 2010: UCB Reports Neupro Provided Clinically Relevant Improvements In Health-Related Quality Of Life For People With Parkinson's Disease
Financial Deals Landscape
UCB Group, Deals Summary, 2004 to 2011
UCB Group Detailed Deal Summary
Proteros Biostructures Enters Into Co-Development Agreement With UCB Group
OM PHARMA Enters Into Partnership Agreement With UCB
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
UCB Group – Pipeline by Therapy Area and Indication, 2011
UCB Group – Pipeline by Stage of Development, 2011
UCB Group – Monotherapy Products in Pipeline, 2011
UCB Group – Combination Treatment Modalities in Pipeline, 2011
UCB Group – Filed, 2011
UCB Group – Phase III, 2011
UCB Group - Phase II, 2011
UCB Group - Phase I, 2011
UCB Group - Pipeline By Therapeutic Class, 2011
UCB Group - Pipeline By Target, 2011
UCB Group – Pipeline By Route of Administration, 2011
UCB Group – Pipeline By Molecule Type, 2011
UCB Group – Recent Pipeline Updates, 2011
UCB Group - Dormant Developmental Projects, 2010
UCB Group - Discontinued Pipeline Products, 2010
UCB Group, Subsidiaries
UCB Group, Deals Summary, 2004 to 2011
UCB Group, Deals Summary, 2004 to 2011
LIST OF FIGURES
UCB Group – Pipeline by Therapy Area and Indication, 2011
UCB Group – Pipeline by Stage of Development, 2011
UCB Group – Monotherapy Products in Pipeline, 2011
UCB Group – Combination Treatment Modalities in Pipeline, 2011
UCB Group – Pipeline By Therapeutic Class, 2011
UCB Group - Pipeline By Target, 2011
UCB Group – Pipeline By Route of Administration, 2011
UCB Group – Pipeline By Molecule Type, 2011
List of Tables
List of Figures
UCB Group Snapshot
UCB Group Overview
Key Information
Key Facts
UCB Group – Research and Development Overview
Key Therapeutic Areas
UCB Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
UCB Group – Pipeline Products Glance
UCB Group – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
UCB Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
UCB Group – Drug Profiles
Rotigotine
Product Description
Mechanism of Action
R&D Progress
Brivaracetam
Product Description
Mechanism of Action
R&D Progress
Cimzia
Product Description
Mechanism of Action
R&D Progress
Vimpat
Product Description
Mechanism of Action
R&D Progress
Brivaracetam
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
CDP6038
Product Description
Mechanism of Action
R&D Progress
CDP791
Product Description
Mechanism of Action
R&D Progress
Keppra
Product Description
Mechanism of Action
R&D Progress
Rotigotine
Product Description
Mechanism of Action
R&D Progress
Vimpat
Product Description
Mechanism of Action
R&D Progress
CDP7657
Product Description
Mechanism of Action
R&D Progress
UCB 2892
Product Description
Mechanism of Action
R&D Progress
UCB Group – Pipeline Analysis
UCB Group – Pipeline Products by Therapeutic Class
UCB Group - Pipeline Products By Target
UCB Group – Pipeline Products by Route of Administration
UCB Group – Pipeline Products by Molecule Type
UCB Group – Recent Pipeline Updates
UCB Group - Dormant Projects
UCB Group - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Alprostadil
CDP 484
CDP 571
CDP 860
CDP323
UCB4412
Vimpat
UCB Group – Company Statement
UCB Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 14, 2010: Immunomedics And UCB Initiate Phase III Program With Epratuzumab In Systemic Lupus Erythematosus
Dec 10, 2010: UCB Reports Study Results Of Neupro In Parkinson’s Disease
Dec 07, 2010: UCB Reports Long-term Use Of Vimpat C-V Effectively Reduces Partial-Onset Seizure Frequency
Dec 01, 2010: Synosia Announces Publication Of Data On SYN-115 In The Journal of Neuroscience
Nov 23, 2010: UCB Reports Neupro Improved Motor, Sleep And Non-Motor Symptoms Of Parkinson’s Disease In Large-scale Study
Nov 05, 2010: UCB To Present Data On Cimzia For Treatment Of Rheumatoid Arthritis At ACR Meeting
Nov 05, 2010: UCB To Present Data On Cimzia For Treatment Of Rheumatoid Arthritis At ACR Meeting
Oct 18, 2010: UCB Presents Growing Body Of Long-term Efficacy Data At ACG 2010 Meeting To Further Support Treatment With Cimzia In Crohn's Disease
Oct 15, 2010: UCB To Present Long-Term Data On Cimzia For Moderate To Severe Crohn's Disease At ACG Annual Meeting
Sep 30, 2010: UCB Reports Neupro Provided Clinically Relevant Improvements In Health-Related Quality Of Life For People With Parkinson's Disease
Financial Deals Landscape
UCB Group, Deals Summary, 2004 to 2011
UCB Group Detailed Deal Summary
Proteros Biostructures Enters Into Co-Development Agreement With UCB Group
OM PHARMA Enters Into Partnership Agreement With UCB
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
UCB Group – Pipeline by Therapy Area and Indication, 2011
UCB Group – Pipeline by Stage of Development, 2011
UCB Group – Monotherapy Products in Pipeline, 2011
UCB Group – Combination Treatment Modalities in Pipeline, 2011
UCB Group – Filed, 2011
UCB Group – Phase III, 2011
UCB Group - Phase II, 2011
UCB Group - Phase I, 2011
UCB Group - Pipeline By Therapeutic Class, 2011
UCB Group - Pipeline By Target, 2011
UCB Group – Pipeline By Route of Administration, 2011
UCB Group – Pipeline By Molecule Type, 2011
UCB Group – Recent Pipeline Updates, 2011
UCB Group - Dormant Developmental Projects, 2010
UCB Group - Discontinued Pipeline Products, 2010
UCB Group, Subsidiaries
UCB Group, Deals Summary, 2004 to 2011
UCB Group, Deals Summary, 2004 to 2011
LIST OF FIGURES
UCB Group – Pipeline by Therapy Area and Indication, 2011
UCB Group – Pipeline by Stage of Development, 2011
UCB Group – Monotherapy Products in Pipeline, 2011
UCB Group – Combination Treatment Modalities in Pipeline, 2011
UCB Group – Pipeline By Therapeutic Class, 2011
UCB Group - Pipeline By Target, 2011
UCB Group – Pipeline By Route of Administration, 2011
UCB Group – Pipeline By Molecule Type, 2011
